Drug Patents Expiring in 2034

1. Drug name - ABILIFY MAINTENA KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10525057 OTSUKA PHARM CO LTD Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function Mar, 2034

(11 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Treatment: Maintenance monotherapy treatment of bipolar 1 disorder; treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia; treatment of schizophrenia

Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage
Strength Dosage Availability
300MG/VIAL FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
300MG FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
400MG/VIAL FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
400MG FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription

2. Drug name - ABRAXANE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9511046 ABRAXIS BIOSCIENCE Methods of treating pancreatic cancer Jan, 2034

(11 years from now)

US9511046

(Pediatric)

ABRAXIS BIOSCIENCE Methods of treating pancreatic cancer Jul, 2034

(11 years from now)

Drugs and Companies using PACLITAXEL ingredient

Treatment: Treatment of pancreatic cancer

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
100MG/VIAL POWDER;INTRAVENOUS Prescription

3. Drug name - ADEMPAS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10662188 BAYER HLTHCARE Forms of methyl {4,6-diamino-2-[1 (2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate
Feb, 2034

(11 years from now)

US11203593 BAYER HLTHCARE Forms of methyl {4,6-diamino-2-[1(2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate
Feb, 2034

(11 years from now)

EP2958914A1 BAYER HLTHCARE Forms Of Methyl {4,6-Diamino-2-[1-(2-Fluorobenzyl)-1H-Pyrazolo[3,4-B]Pyridino-3-Yl]Pyrimidino-5-Yl}Methyl Carbamate
Feb, 2034

(11 years from now)

EP2958914B1 BAYER HLTHCARE Forms Of Methyl {4,6-Diamino-2-[1-(2-Fluorobenzyl)-1H-Pyrazolo[3,4-B]Pyridino-3-Yl]Pyrimidino-5-Yl}Methyl Carbamate
Feb, 2034

(11 years from now)

Drugs and Companies using RIOCIGUAT ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
0.5MG TABLET;ORAL Prescription
1MG TABLET;ORAL Prescription
1.5MG TABLET;ORAL Prescription
2MG TABLET;ORAL Prescription
2.5MG TABLET;ORAL Prescription

4. Drug name - AIRDUO DIGIHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9066957 TEVA PHARM Dry powder inhaler Oct, 2034

(12 years from now)

US9415008 TEVA PHARM Dry powder inhaler Oct, 2034

(12 years from now)

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Treatment: Treatment of asthma

Dosage: POWDER;INHALATION

More Information on Dosage
Strength Dosage Availability
0.055MG/INH;EQ 0.014MG BASE/INH POWDER;INHALATION Prescription
0.113MG/INH;EQ 0.014MG BASE/INH POWDER;INHALATION Prescription
0.232MG/INH;EQ 0.014MG BASE/INH POWDER;INHALATION Prescription

5. Drug name - ALKINDI SPRINKLE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9649280 ETON Composition comprising hydrocortisone May, 2034

(11 years from now)

Drugs and Companies using HYDROCORTISONE ingredient

Treatment: Treatment of adrenal insufficiency

Dosage: GRANULE;ORAL

More Information on Dosage
Strength Dosage Availability
0.5MG GRANULE;ORAL Prescription
1MG GRANULE;ORAL Prescription
2MG GRANULE;ORAL Prescription
5MG GRANULE;ORAL Prescription

6. Drug name - ALUNBRIG

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9611283 TAKEDA PHARMS USA Methods for inhibiting cell proliferation in ALK-driven cancers Apr, 2034

(11 years from now)

Drugs and Companies using BRIGATINIB ingredient

Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
30MG TABLET;ORAL Prescription
90MG TABLET;ORAL Prescription
180MG TABLET;ORAL Prescription

7. Drug name - ARIKAYCE KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9566234 INSMED INC Systems for treating pulmonary infections Jan, 2034

(11 years from now)

Drugs and Companies using AMIKACIN SULFATE ingredient

Treatment: Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination antibacterial drug regimen

Dosage: SUSPENSION, LIPOSOMAL;INHALATION

More Information on Dosage
Strength Dosage Availability
EQ 590MG BASE/8.4ML SUSPENSION, LIPOSOMAL;INHALATION Prescription

8. Drug name - AUBAGIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9186346 SANOFI AVENTIS US Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients Feb, 2034

(11 years from now)

US9186346

(Pediatric)

SANOFI AVENTIS US Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients Aug, 2034

(11 years from now)

Drugs and Companies using TERIFLUNOMIDE ingredient

Treatment: Treatment of patients with relapsing forms of multiple sclerosis while managing the risk of teriflunomide and rosuvastatin interaction by limiting the rosuvastatin dose to no more than 10mg and/or administering about half the normal dose

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
7MG TABLET;ORAL Prescription
14MG TABLET;ORAL Prescription

9. Drug name - AUSTEDO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9296739

(Pediatric)

TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 Mar, 2034

(11 years from now)

US9814708

(Pediatric)

TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 Mar, 2034

(11 years from now)

US9233959

(Pediatric)

TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 Mar, 2034

(11 years from now)

US9550780

(Pediatric)

TEVA BRANDED PHARM Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 Mar, 2034

(11 years from now)

More Information on Dosage
Strength Dosage Availability
6MG TABLET;ORAL Prescription
9MG TABLET;ORAL Prescription
12MG TABLET;ORAL Prescription

10. Drug name - AYVAKIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9994575 BLUEPRINT MEDICINES Compositions useful for treating disorders related to kit
Oct, 2034

(12 years from now)

US9200002 BLUEPRINT MEDICINES Compositions useful for treating disorders related to KIT
Oct, 2034

(12 years from now)

US9944651 BLUEPRINT MEDICINES Compositions useful for treating disorders related to kit
Oct, 2034

(12 years from now)

CN105658652A BLUEPRINT MEDICINES Composition For Treating Kit Disorders
Oct, 2034

(12 years from now)

CN105658652B BLUEPRINT MEDICINES Compound That Can Be Used To Treat A Disorder Associated With Kit
Oct, 2034

(12 years from now)

IN341186B BLUEPRINT MEDICINES Compositions Useful For Treating Disorders Related To Kit
Oct, 2034

(12 years from now)

IN201617009956A BLUEPRINT MEDICINES Compositions Useful For Treating Disorders Related To Kit
Oct, 2034

(12 years from now)

EP3409674A1 BLUEPRINT MEDICINES Process For Preparing Compositions Useful For Treating Disorders Related To Kit
Oct, 2034

(12 years from now)

EP3409674B1 BLUEPRINT MEDICINES Process For Preparing Compositions Useful For Treating Disorders Related To Kit
Oct, 2034

(12 years from now)

EP3057969B1 BLUEPRINT MEDICINES Compositions Useful For Treating Disorders Related To Kit
Oct, 2034

(12 years from now)

EP3057969A1 BLUEPRINT MEDICINES Compositions Useful For Treating Disorders Related To Kit
Oct, 2034

(12 years from now)

More Information on Dosage
Strength Dosage Availability
25MG TABLET;ORAL Prescription
50MG TABLET;ORAL Prescription
100MG TABLET;ORAL Prescription
200MG TABLET;ORAL Prescription
300MG TABLET;ORAL Prescription

11. Drug name - BOSULIF

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11103497 PF PRISM CV Treatment of imatinib resistant leukemia Feb, 2034

(11 years from now)

Drugs and Companies using BOSUTINIB MONOHYDRATE ingredient

Treatment: A method for treating a bcrabl positive leukemia in a subject that is resistant to imatinib comprising administering to the subject a therapeutically effective amount of bosutinib, wherein the subject has a mutation in the bcrabl protein at 949t>c; a method for treating a bcrabl positive leukemia in a subject that is resistant to imatinib comprising administering to the subject a therapeutically effective amount of bosutinib, wherein the subject has a mutation in the bcrabl protein at f317l

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 100MG BASE TABLET;ORAL Prescription
EQ 400MG BASE TABLET;ORAL Prescription
EQ 500MG BASE TABLET;ORAL Prescription

12. Drug name - BRUKINSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10570139 BEIGENE Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators
Apr, 2034

(11 years from now)

US11142528 BEIGENE Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators
Apr, 2034

(11 years from now)

US9447106 BEIGENE Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators
Apr, 2034

(11 years from now)

IN201503521P2 BEIGENE Fused Heterocyclic Compounds As Protein Kinase Inhibitors
Apr, 2034

(11 years from now)

IN370291B BEIGENE Fused Heterocyclic Compounds As Protein Kinase Inhibitors
Apr, 2034

(11 years from now)

Drugs and Companies using ZANUBRUTINIB ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
80MG CAPSULE;ORAL Prescription

13. Drug name - CAPLYTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9956227 INTRA-CELLULAR Method for the treatment of residual symptoms of schizophrenia Dec, 2034

(12 years from now)

US11026951 INTRA-CELLULAR Methods of treating bipolar disorder Dec, 2034

(12 years from now)

US10960009 INTRA-CELLULAR Methods of treating schizophrenia and depression Dec, 2034

(12 years from now)

Drugs and Companies using LUMATEPERONE TOSYLATE ingredient

Treatment: Treatment of schizophrenia with improvement in residual symptoms of schizophrenia; Treatment of bipolar i disorder, bipolar ii disorder, or bipolar depression; Treatment of schizophrenia

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 42MG BASE CAPSULE;ORAL Prescription

14. Drug name - CIBINQO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9545405 PFIZER Pyrrolo[2,3-D]pyrimidine derivatives
Feb, 2034

(11 years from now)

US9035074 PFIZER Pyrrolo[2,3-D]pyrimidine derivatives
Feb, 2034

(11 years from now)

CN105008362A PFIZER Pyrrolo [2, 3-D] Pyrimidine Derivative Used As James Related Kinase (As Jak) Inhibitor
Feb, 2034

(11 years from now)

CN105008362B PFIZER As Associated Janus Kinase (Jak) Inhibitor Of Pyrrolo [2 3-D] Pyrimidine Derivatives
Feb, 2034

(11 years from now)

CN107089985A PFIZER As The Janus Kinase (Jak) Inhibitors Of Pyrrolo [2, 3-D] Pyrimidine Derivatives
Feb, 2034

(11 years from now)

CN107089985B PFIZER As The Janus Kinase (Jak) Inhibitors Of Pyrrolo [2, 3-D] Pyrimidine Derivatives
Feb, 2034

(11 years from now)

IN201506803P1 PFIZER Pyrrolo [2 3 D]Pyrimidine Derivatives As Inhibitors Of Janus Related Kinases (Jak)
Feb, 2034

(11 years from now)

IN329290B PFIZER Pyrrolo [2, 3, D]Pyrimidine Derivatives As Inhibitors Of Janus Related Kinases (Jak)
Feb, 2034

(11 years from now)

EP3290421A1 PFIZER Combination Of Pyrrolo [2, 3 -D]Pyrimidine Derivatives With One Or More Additional Agents As Inhibitors Of Janus- Related Kinases (Jak)
Feb, 2034

(11 years from now)

EP3290421B1 PFIZER Combination Of Pyrrolo [2, 3 -D]Pyrimidine Derivatives With One Or More Additional Agents As Inhibitors Of Janus- Related Kinases (Jak)
Feb, 2034

(11 years from now)

EP2958921B1 PFIZER Pyrrolo [2, 3 -D]Pyrimidine Derivatives As Inhibitors Of Janus Kinases (Jak)
Feb, 2034

(11 years from now)

EP2958921A1 PFIZER Pyrrolo [2, 3 -D]Pyrimidine Derivatives As Inhibitors Of Janus Kinases (Jak)
Feb, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9549929 PFIZER Pyrrolo[2,3-D]pyrimidine derivatives Feb, 2034

(11 years from now)

Drugs and Companies using ABROCITINIB ingredient

Treatment: Treatment of adults with refractory, moderate-to-severe atopic dermatitis not adequately controlled with other systemic drug products or when use of those therapies is inadvisable

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
50MG TABLET;ORAL Prescription
100MG TABLET;ORAL Prescription
200MG TABLET;ORAL Prescription

15. Drug name - CLENPIQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10624879 FERRING PHARMS INC Liquid pharmaceutical composition Jun, 2034

(11 years from now)

US11191753 FERRING PHARMS INC Liquid pharmaceutical composition Jun, 2034

(11 years from now)

US9827231 FERRING PHARMS INC Liquid pharmaceutical composition Jun, 2034

(11 years from now)

Drugs and Companies using CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE ingredient

Treatment: For cleansing of the colon as a preparation for colonoscopy; For cleansing the large intestine as a preparation for colonoscopy

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
12GM/BOT;3.5GM/BOT;10MG/BOT SOLUTION;ORAL Prescription

16. Drug name - CONTRAVE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10835527 NALPROPION Compositions and methods for reducing major adverse cardiovascular events Jul, 2034

(11 years from now)

US10231964 NALPROPION Compositions and methods for weight loss in at risk patient populations Jul, 2034

(11 years from now)

US10828294 NALPROPION Compositions and methods for weight loss in at risk patient populations Jul, 2034

(11 years from now)

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Treatment: For chronic weight management for treating overweight or obesity

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
90MG;8MG TABLET, EXTENDED RELEASE;ORAL Prescription

17. Drug name - COSELA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10966984 G1 THERAP Transient protection of normal cells during chemotherapy Mar, 2034

(11 years from now)

US9487530 G1 THERAP Transient protection of normal cells during chemotherapy Mar, 2034

(11 years from now)

US10085992 G1 THERAP Transient protection of normal cells during chemotherapy Mar, 2034

(11 years from now)

US11040042 G1 THERAP Transient protection of normal cells during chemotherapy Mar, 2034

(11 years from now)

Drugs and Companies using TRILACICLIB DIHYDROCHLORIDE ingredient

Treatment: A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen for extensive-stage small cell lung cancer; a method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a topotecan-containing regimen for extensive- stage small cell lung cancer; A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a carboplatin and etoposide-containing regimen for extensive-stage small cell lung cancer

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 300MG BASE/VIAL POWDER;INTRAVENOUS Prescription

18. Drug name - COTELLIC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11087354 GENENTECH INC Combination therapies Jun, 2034

(11 years from now)

Drugs and Companies using COBIMETINIB FUMARATE ingredient

Treatment: Method of using cobimetinib for the treatment of melanoma

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE TABLET;ORAL Prescription

19. Drug name - DEXYCU KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10159683 EYEPOINT PHARMS Use of sustained release dexamethasone in post-cataract surgery inflammation May, 2034

(11 years from now)

US10028965 EYEPOINT PHARMS Use of sustained release dexamethasone in post-cataract surgery inflammation May, 2034

(11 years from now)

US10022502 EYEPOINT PHARMS Dose guides for injection syringe Jun, 2034

(11 years from now)

Drugs and Companies using DEXAMETHASONE ingredient

Treatment: Treatment of postoperative inflammation

Dosage: SUSPENSION;INTRAOCULAR

More Information on Dosage
Strength Dosage Availability
9% SUSPENSION;INTRAOCULAR Prescription

20. Drug name - DIFICID

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9808530 CUBIST PHARMS LLC Composition of tiacumicin compounds May, 2034

(11 years from now)

US9808530

(Pediatric)

CUBIST PHARMS LLC Composition of tiacumicin compounds Nov, 2034

(12 years from now)

Drugs and Companies using FIDAXOMICIN ingredient

Treatment: NA

Dosage: FOR SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
40MG/ML FOR SUSPENSION;ORAL Prescription

21. Drug name - DILAUDID

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9248229 FRESENIUS KABI USA Packaging system for oxygen-sensitive drugs Mar, 2034

(11 years from now)

More Information on Dosage
Strength Dosage Availability
0.2MG/ML INJECTABLE;INJECTION Prescription
1MG/ML INJECTABLE;INJECTION Prescription
2MG/ML INJECTABLE;INJECTION Prescription
4MG/ML INJECTABLE;INJECTION Discontinued
10MG/ML INJECTABLE;INJECTION Discontinued
250MG/VIAL INJECTABLE;INJECTION Discontinued

22. Drug name - DORYX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9295652 MAYNE PHARMA Controlled release doxycycline Oct, 2034

(12 years from now)

US9511031 MAYNE PHARMA Controlled release doxycycline Oct, 2034

(12 years from now)

US9446057 MAYNE PHARMA Controlled release doxycycline Dec, 2034

(12 years from now)

Drugs and Companies using DOXYCYCLINE HYCLATE ingredient

Treatment: To treat or prevent infections caused by susceptible bacteria using delayed-release tablets consisting of doxycycline hyclate coated pellets in a tablet

Dosage: TABLET, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE TABLET, DELAYED RELEASE;ORAL Prescription
EQ 75MG BASE TABLET, DELAYED RELEASE;ORAL Prescription
EQ 80MG BASE TABLET, DELAYED RELEASE;ORAL Prescription
EQ 100MG BASE TABLET, DELAYED RELEASE;ORAL Prescription
EQ 150MG BASE TABLET, DELAYED RELEASE;ORAL Prescription
EQ 200MG BASE TABLET, DELAYED RELEASE;ORAL Prescription
EQ 60MG BASE TABLET, DELAYED RELEASE;ORAL Discontinued
EQ 120MG BASE TABLET, DELAYED RELEASE;ORAL Prescription

23. Drug name - DURYSTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9492316 ALLERGAN INC Prostamide-containing intraocular implants and methods of use thereof Oct, 2034

(12 years from now)

US9980974 ALLERGAN INC Prostamide-containing intraocular implants and methods of use thereof Oct, 2034

(12 years from now)

Drugs and Companies using BIMATOPROST ingredient

Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant

Dosage: IMPLANT;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
10MCG IMPLANT;OPHTHALMIC Prescription

24. Drug name - EPCLUSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11116783 GILEAD SCIENCES INC Combination formulation of two antiviral compounds Jan, 2034

(11 years from now)

US10086011 GILEAD SCIENCES INC Combination formulation of two antiviral compounds Jan, 2034

(11 years from now)

US9757406 GILEAD SCIENCES INC Combination formulation of two antiviral compounds Jan, 2034

(11 years from now)

US11116783

(Pediatric)

GILEAD SCIENCES INC Combination formulation of two antiviral compounds Jul, 2034

(11 years from now)

US10086011

(Pediatric)

GILEAD SCIENCES INC Combination formulation of two antiviral compounds Jul, 2034

(11 years from now)

US9757406

(Pediatric)

GILEAD SCIENCES INC Combination formulation of two antiviral compounds Jul, 2034

(11 years from now)

Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient

Treatment: For the treatment of hepatitis c

Dosage: PELLETS;ORAL

More Information on Dosage
Strength Dosage Availability
150MG;37.5MG/PACKET PELLETS;ORAL Prescription
200MG;50MG/PACKET PELLETS;ORAL Prescription

25. Drug name - EPIDIOLEX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11154516 GW RES LTD Use of cannabinoids in the treatment of epilepsy Jun, 2034

(11 years from now)

Drugs and Companies using CANNABIDIOL ingredient

Treatment: Use for the treatment of seizures associated with dravet syndrome; use for the treatment of seizures associated with lennox-gastaut syndrome

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
100MG/ML SOLUTION;ORAL Prescription

26. Drug name - EPINEPHRINE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039728 BELCHER More potent and less toxic formulations of epinephrine and methods of medical use Aug, 2034

(11 years from now)

US10004700 BELCHER More potent and less toxic formulations of epinephrine and methods of medical use Aug, 2034

(11 years from now)

US9283197 BELCHER More potent and less toxic formulations of epinephrine and methods of medical use Aug, 2034

(11 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Treatment: Increasing mean arterial blood pressure in adult patients with hypotension associated with septic shock; Emergency treatment of allergic reactions (type 1), including anaphylaxis; a method of treating allergic reaction, anaphylaxis, anaphylactic shock, or combination thereof by an injection of at least one dosage of the injectable liquid pharmaceutical; Emergency treatment of allergic reactions (type i), including anaphylaxis; increasing mean arterial blood pressure in adult patients with hypotension associated with septic shock; induction and maintenance of mydriasis during intraocular surgery

Dosage: SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 1MG BASE/ML (EQ 1MG BASE/ML) SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS Prescription

27. Drug name - EVOMELA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10040872 ACROTECH Alkylated cyclodextrin compositions and processes for preparing and using the same Jan, 2034

(11 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE/VIAL POWDER;INTRAVENOUS Prescription

28. Drug name - EVZIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9517307 KALEO INC Devices and methods for delivering opioid antagonists including formulations for naloxone Jul, 2034

(11 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Treatment: Use of an auto injector to administer naloxone hcl

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
0.4MG/0.4ML (0.4MG/0.4ML) SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS Discontinued

29. Drug name - EVZIO (AUTOINJECTOR)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9517307 KALEO INC Devices and methods for delivering opioid antagonists including formulations for naloxone Jul, 2034

(11 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Treatment: Use of an auto injector to administer naloxone hcl

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
2MG/0.4ML (2MG/0.4ML) SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS Discontinued

30. Drug name - EXONDYS 51

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9506058 SAREPTA THERAPS INC Compositions for treating muscular dystrophy Mar, 2034

(11 years from now)

US10364431 SAREPTA THERAPS INC Compositions for treating muscular dystrophy Mar, 2034

(11 years from now)

US10337003 SAREPTA THERAPS INC Compositions for treating muscular dystrophy Mar, 2034

(11 years from now)

Drugs and Companies using ETEPLIRSEN ingredient

Treatment: Treatment of duchenne muscular dystrophy in patients having a mutation of the dmd gene that is amenable to exon 51 skipping; restoring an mrna reading frame to induce dystrophin protein production in patients having a mutation of the dmd gene that is amenable to exon 51 skipping; Restoring an mrna reading frame to induce dystrophin protein production in patients having a mutation of the dmd gene that is amenable to exon 51 skipping; treatment of duchenne muscular dystrophy in patients having a mutation of the dmd gene that is amenable to exon 51 skipping; Treatment of duchenne muscular dystrophy in patients having a mutation of the dmd gene that is amenable to exon 51 skipping

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
100MG/2ML (50MG/ML) SOLUTION;INTRAVENOUS Prescription
500MG/10ML (50MG/ML) SOLUTION;INTRAVENOUS Prescription

31. Drug name - FIRDAPSE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10793893 CATALYST PHARMS Methods of administering 3,4-diaminopyridine Apr, 2034

(11 years from now)

Drugs and Companies using AMIFAMPRIDINE PHOSPHATE ingredient

Treatment: Method of treating lambert-eaton myasthenic syndrome with amifampridine

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 10MG BASE TABLET;ORAL Prescription

32. Drug name - FULVESTRANT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9833459 FRESENIUS KABI USA Fulvestrant formulations Feb, 2034

(11 years from now)

US10188663 FRESENIUS KABI USA Fulvestrant formulations Feb, 2034

(11 years from now)

US9271990 FRESENIUS KABI USA Fulvestrant formulations May, 2034

(11 years from now)

Drugs and Companies using FULVESTRANT ingredient

Treatment: Treatment of hormone receptor positive advanced breast cancer in postmenopausal women

Dosage: SOLUTION;INTRAMUSCULAR

More Information on Dosage
Strength Dosage Availability
250MG/5ML (50MG/ML) SOLUTION;INTRAMUSCULAR Prescription

33. Drug name - GANZYK-RTU

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9486530 EXELA PHARMA Ganciclovir compositions and related methods Sep, 2034

(11 years from now)

Drugs and Companies using GANCICLOVIR ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
500MG/250ML (2MG/ML) SOLUTION;INTRAVENOUS Prescription

34. Drug name - GIAPREZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11096983 LA JOLLA PHARMA Angiotensin II alone or in combination for the treatment of hypotension Dec, 2034

(12 years from now)

US10493124 LA JOLLA PHARMA Angiotensin II alone or in combination for the treatment of hypotension Dec, 2034

(12 years from now)

US9220745 LA JOLLA PHARMA Angiotensin II alone or in combination for the treatment of hypotension Dec, 2034

(12 years from now)

US10028995 LA JOLLA PHARMA Angiotensin II alone or in combination for the treatment of hypotension Dec, 2034

(12 years from now)

Drugs and Companies using ANGIOTENSIN II ACETATE ingredient

Treatment: Treating distributive shock with angiotensin ii; treating septic shock with angiotensin ii; Treating low blood pressure with angiotensin ii at an initial rate of about 20 ng/kg/min and titrating down to achieve and/or maintain a map of about 65 mm hg or above; Maintaining mean arterial pressure of about 65 mmhg or higher with angiotensin ii in shock patients treated with catecholamines and reducing catecholamine use; treating high output shock with angiotensin ii by increasing mean arterial pressure in patients treated with catecholamines and reducing catecholamine use; Maintaining mean arterial pressure of about 65 mmhg or above with about 1 ng/kg/min to about 40 ng/kg/min angiotensin ii in hypotensive patients treated with vasopressin or a vasopressin analogue and reducing vasopressin or vasopressin analogue use

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 0.5MG BASE/ML (EQ 0.5MG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML) SOLUTION;INTRAVENOUS Discontinued

35. Drug name - GIVLAARI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10119143 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene
Oct, 2034

(12 years from now)

US11028392 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene
Oct, 2034

(12 years from now)

CN105980559A ALNYLAM PHARMS INC Composition And Method For Inhibition Of Alas1 Gene Expression
Oct, 2034

(12 years from now)

CN105980559B ALNYLAM PHARMS INC Composition And Method For Inhibiting Alas1 Gene Expression
Oct, 2034

(12 years from now)

IN201647014609A ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of The Alas1 Gene
Oct, 2034

(12 years from now)

IN392668B ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of The Alas1 Gene
Oct, 2034

(12 years from now)

EP3052628A1 ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of The Alas1 Gene
Oct, 2034

(12 years from now)

EP3052628B1 ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of The Alas1 Gene
Oct, 2034

(12 years from now)

Drugs and Companies using GIVOSIRAN SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 189MG BASE/ML (EQ 189MG BASE/ML) SOLUTION;SUBCUTANEOUS Prescription

36. Drug name - GLYXAMBI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof Apr, 2034

(11 years from now)

US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof Apr, 2034

(11 years from now)

US9949998 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof Jun, 2034

(11 years from now)

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient

Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (30 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
10MG;5MG TABLET;ORAL Prescription
25MG;5MG TABLET;ORAL Prescription

37. Drug name - GOCOVRI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10646456 ADAMAS PHARMA Methods of administering amantadine Jun, 2034

(11 years from now)

US10154971 ADAMAS PHARMA Methods of administering amantadine Dec, 2034

(12 years from now)

Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient

Treatment: Treatment of dyskinesia, decreasing off time, and increasing on time without troublesome dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; Treatment of dyskinesia and decreasing off time in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 68.5MG BASE CAPSULE, EXTENDED RELEASE;ORAL Prescription
EQ 137MG BASE CAPSULE, EXTENDED RELEASE;ORAL Prescription

38. Drug name - HARVONI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10039779 GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jan, 2034

(11 years from now)

CN105748499A GILEAD SCIENCES INC Coupling Preparation Of Two Antiviral Compounds
Jan, 2034

(11 years from now)

CN105748499B GILEAD SCIENCES INC A Combined Preparation Of Two Antiviral Compounds
Jan, 2034

(11 years from now)

EP2950786B1 GILEAD SCIENCES INC Combination Formulation Of Two Antiviral Compounds
Jan, 2034

(11 years from now)

EP2950786A1 GILEAD SCIENCES INC Combination Formulation Of Two Antiviral Compounds
Jan, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039779

(Pediatric)

GILEAD SCIENCES INC Combination formulation of two antiviral compounds Jul, 2034

(11 years from now)

More Information on Dosage
Strength Dosage Availability
45MG;200MG TABLET;ORAL Prescription
90MG;400MG TABLET;ORAL Prescription

39. Drug name - HETLIOZ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9730910 VANDA PHARMS INC Treatment of circadian rhythm disorders May, 2034

(11 years from now)

US10610511 VANDA PHARMS INC Method of treatment Oct, 2034

(12 years from now)

US11141400 VANDA PHARMS INC Method of treatment Oct, 2034

(12 years from now)

Drugs and Companies using TASIMELTEON ingredient

Treatment: Treatment of non-24-hour sleep-wake disorder by avoiding the use of tasimelteon in combination with rifampin; treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the use of tasimelteon with rifampin; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food; treatment of non-24 hour sleep-wake disorder by avoiding the administration of tasimelteon with food; Treatment of non-24 hour sleep-wake disorder by avoiding the administration of tasimelteon with food; treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
20MG CAPSULE;ORAL Prescription

40. Drug name - HETLIOZ LQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9730910 VANDA PHARMS INC Treatment of circadian rhythm disorders May, 2034

(11 years from now)

US10610511 VANDA PHARMS INC Method of treatment Oct, 2034

(12 years from now)

US11141400 VANDA PHARMS INC Method of treatment Oct, 2034

(12 years from now)

Drugs and Companies using TASIMELTEON ingredient

Treatment: Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the use of tasimelteon with rifampin; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food

Dosage: SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
4MG/ML SUSPENSION;ORAL Prescription

41. Drug name - IBRANCE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10723730 PFIZER Solid forms of a selective CDK4/6 inhibitor
Feb, 2034

(11 years from now)

EP3431475A1 PFIZER Solid Forms Of A Selective Cdk4/6 Inhibitor
Feb, 2034

(11 years from now)

EP3431475B1 PFIZER Solid Forms Of A Selective Cdk4/6 Inhibitor
Feb, 2034

(11 years from now)

EP2958916A1 PFIZER Solid Forms Of A Selective Cdk4/6 Inhibitor
Feb, 2034

(11 years from now)

EP2958916B1 PFIZER Solid Forms Of A Selective Cdk4/6 Inhibitor
Feb, 2034

(11 years from now)

Drugs and Companies using PALBOCICLIB ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
75MG CAPSULE;ORAL Prescription
100MG CAPSULE;ORAL Prescription
125MG CAPSULE;ORAL Prescription

42. Drug name - IDHIFA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9738625 CELGENE CORP Therapeutically active compounds and their methods of use
Aug, 2034

(11 years from now)

US10093654 CELGENE CORP Therapeutically active compounds and their methods of use
Aug, 2034

(11 years from now)

US9732062 CELGENE CORP Therapeutically active compounds and their methods of use
Sep, 2034

(11 years from now)

EP3566706B1 CELGENE CORP Therapeutically Active Compounds And Their Methods Of Use
Aug, 2034

(11 years from now)

EP3566706A1 CELGENE CORP Therapeutically Active Compounds And Their Methods Of Use
Aug, 2034

(11 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE TABLET;ORAL Prescription
EQ 100MG BASE TABLET;ORAL Prescription

43. Drug name - IMBRUVICA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10463668 PHARMACYCLICS INC Methods of treating and preventing graft versus host disease Oct, 2034

(12 years from now)

US10695350 PHARMACYCLICS INC Methods of treating and preventing graft versus host disease Oct, 2034

(12 years from now)

US9795604 PHARMACYCLICS INC Methods of treating and preventing graft versus host disease Oct, 2034

(12 years from now)

Drugs and Companies using IBRUTINIB ingredient

Treatment: Treatment of refractory chronic graft-versus-host disease; Treatment of chronic graft versus host disease refractory to systemic therapy; Treatment of adult patients with chronic graft-versus-host disease (cgvhd) after failure of one or more lines of systemic therapy; treatment of adult patients with cyclosporin-resistant, steroid-dependent/refractory, or steroid resistant chronic graft-versus-host disease (cgvhd) after failure of one or more lines of systemic therapy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
140MG TABLET;ORAL Prescription
280MG TABLET;ORAL Prescription
420MG TABLET;ORAL Prescription
560MG TABLET;ORAL Prescription

44. Drug name - IMCIVREE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11129869 RHYTHM Pharmaceutical compositions Jul, 2034

(11 years from now)

Drugs and Companies using SETMELANOTIDE ACETATE ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 10MG/ML BASE (EQ 10MG/ML BASE) SOLUTION;SUBCUTANEOUS Prescription

45. Drug name - INOMAX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9279794 MALLINCKRODT HOSP Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide Feb, 2034

(11 years from now)

US9279794

(Pediatric)

MALLINCKRODT HOSP Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide Aug, 2034

(11 years from now)

Drugs and Companies using NITRIC OXIDE ingredient

Treatment: A method of providing nitric oxide therapy to a patient by compensating long-term sensitivity drift of electrochemical gas sensors used in systems for delivering therapeutic nitric oxide to a patient

Dosage: GAS;INHALATION

More Information on Dosage
Strength Dosage Availability
100PPM GAS;INHALATION Discontinued
800PPM GAS;INHALATION Prescription

46. Drug name - JADENU

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9283209 NOVARTIS PHARMS CORP Oral formulations of deferasirox
Nov, 2034

(12 years from now)

CN105025886B NOVARTIS PHARMS CORP Oral Preparation Of Deferasirox (Deferasirox)
Mar, 2034

(11 years from now)

CN105025886A NOVARTIS PHARMS CORP Oral Preparation Of Deferasirox (Deferasirox)
Mar, 2034

(11 years from now)

EP3124018A1 NOVARTIS PHARMS CORP Oral Formulations Of Deferasirox
Mar, 2034

(11 years from now)

EP2964202A1 NOVARTIS PHARMS CORP Oral Formulations Of Deferasirox
Mar, 2034

(11 years from now)

EP2964202B1 NOVARTIS PHARMS CORP Oral Formulations Of Deferasirox
Mar, 2034

(11 years from now)

EP3124018B1 NOVARTIS PHARMS CORP Oral Formulations Of Deferasirox
Mar, 2034

(11 years from now)

More Information on Dosage
Strength Dosage Availability
90MG TABLET;ORAL Prescription
180MG TABLET;ORAL Prescription
360MG TABLET;ORAL Prescription

47. Drug name - JARDIANCE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof Apr, 2034

(11 years from now)

US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof Apr, 2034

(11 years from now)

US9949997 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof May, 2034

(11 years from now)

US9949998 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof Jun, 2034

(11 years from now)

Drugs and Companies using EMPAGLIFLOZIN ingredient

Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (30 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of reducing the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular disease by once daily administration of 10 mg or 25 mg of empagliflozin; method for reducing the risk of cardiovascular death plus hospitalization for heart failure in adults with type 2 diabetes mellitus, heart failure and reduced ejection fraction by once daily administration of empagliflozin

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET;ORAL Prescription
25MG TABLET;ORAL Prescription

48. Drug name - JUBLIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10828293 BAUSCH Anti-infective methods, compositions, and devices Oct, 2034

(12 years from now)

US10342875 BAUSCH Stabilized efinaconazole compositions Oct, 2034

(12 years from now)

US10864274 BAUSCH Stabilized efinaconazole formulations Oct, 2034

(12 years from now)

US9662394 BAUSCH Stabilized efinaconazole compositions Oct, 2034

(12 years from now)

Drugs and Companies using EFINACONAZOLE ingredient

Treatment: Antimycotic uses, specifically treatment of onychomycosis; topical treatment of the toenail(s) due to trichophyton rubrum and trichophyton mentagrophytes

Dosage: SOLUTION;TOPICAL

More Information on Dosage
Strength Dosage Availability
10% SOLUTION;TOPICAL Prescription

49. Drug name - KLOXXADO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10973814 HIKMA Liquid naloxone spray Aug, 2034

(11 years from now)

US10722510 HIKMA Liquid naloxone spray Aug, 2034

(11 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Treatment: Use of naloxone for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients

Dosage: SPRAY;NASAL

More Information on Dosage
Strength Dosage Availability
8MG/SPRAY SPRAY;NASAL Prescription

50. Drug name - LEQVIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10125369 NOVARTIS PCSK9 iRNA compositions and methods of use thereof
Aug, 2034

(11 years from now)

Drugs and Companies using INCLISIRAN SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 284MG BASE/1.5ML (EQ 189MG BASE/ML) SOLUTION;SUBCUTANEOUS Prescription

51. Drug name - LILETTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10028858 MEDICINES360 Intrauterine systems, IUD insertion devices, and related methods and kits therefor Mar, 2034

(11 years from now)

Drugs and Companies using LEVONORGESTREL ingredient

Treatment: A method for prevention of pregnancy

Dosage: INTRAUTERINE DEVICE;INTRAUTERINE

More Information on Dosage
Strength Dosage Availability
52MG INTRAUTERINE DEVICE;INTRAUTERINE Prescription

52. Drug name - LONSURF

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10457666 TAIHO ONCOLOGY Stable crystal form of tipiracil hydrochloride and crystallization method for the same
Jun, 2034

(11 years from now)

US9527833 TAIHO ONCOLOGY Stable crystal form of tipiracil hydrochloride and crystallization method for the same
Jun, 2034

(11 years from now)

EP3012255A4 TAIHO ONCOLOGY Stabilized Crystal Of Tipiracil Hydrochloride, And Crystallization Method For Same
Jun, 2034

(11 years from now)

EP3012255B1 TAIHO ONCOLOGY Stable Crystal Form Of Tipiracil Hydrochloride And Crystallization Method For The Same
Jun, 2034

(11 years from now)

EP3012255A1 TAIHO ONCOLOGY Stable Crystal Form Of Tipiracil Hydrochloride And Crystallization Method For The Same
Jun, 2034

(11 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 6.14MG BASE;15MG TABLET;ORAL Prescription
EQ 8.19MG BASE;20MG TABLET;ORAL Prescription

53. Drug name - LOREEV XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8999393 ALMATICA Sustained release formulations of lorazepam Jan, 2034

(11 years from now)

Drugs and Companies using LORAZEPAM ingredient

Treatment: Once daily treatment of anxiety disorder in adults

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
1MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
1.5MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
2MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
3MG CAPSULE, EXTENDED RELEASE;ORAL Prescription

54. Drug name - LUZU

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8980931 BAUSCH Method of evaluating pharmaceutical preparation containing luliconazole and index substance Apr, 2034

(11 years from now)

Drugs and Companies using LULICONAZOLE ingredient

Treatment: NA

Dosage: CREAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
1% CREAM;TOPICAL Prescription

55. Drug name - MAKENA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9789257 COVIS Needle assisted injection device having reduced trigger force Feb, 2034

(11 years from now)

Drugs and Companies using HYDROXYPROGESTERONE CAPROATE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR; SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
1250MG/5ML (250MG/ML) SOLUTION;INTRAMUSCULAR Prescription
250MG/ML (250MG/ML) SOLUTION;INTRAMUSCULAR Prescription
275MG/1.1ML (250MG/ML) SOLUTION;SUBCUTANEOUS Prescription

56. Drug name - MAVYRET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10286029 ABBVIE INC Method for treating HCV Mar, 2034

(11 years from now)

US10286029

(Pediatric)

ABBVIE INC Method for treating HCV Sep, 2034

(11 years from now)

Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient

Treatment: Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in adult and pediatric patients 12 years and older or weighing at least 45 kg

Dosage: PELLETS;ORAL

More Information on Dosage
Strength Dosage Availability
50MG;20MG/PACKET PELLETS;ORAL Prescription

57. Drug name - MORPHINE SULFATE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9248229 FRESENIUS KABI USA Packaging system for oxygen-sensitive drugs Mar, 2034

(11 years from now)

US9192608 FRESENIUS KABI USA Morphine formulations Mar, 2034

(11 years from now)

US9072781 FRESENIUS KABI USA Morphine formulations Mar, 2034

(11 years from now)

Drugs and Companies using MORPHINE SULFATE ingredient

Treatment: Management of chronic pain in patients requiring opioid analgesia; treatment of pain

Dosage: SOLUTION;INTRAMUSCULAR, INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
2MG/ML (2MG/ML) SOLUTION;INTRAMUSCULAR, INTRAVENOUS Prescription
4MG/ML (4MG/ML) SOLUTION;INTRAMUSCULAR, INTRAVENOUS Prescription
5MG/ML (5MG/ML) SOLUTION;INTRAMUSCULAR, INTRAVENOUS Prescription
8MG/ML (8MG/ML) SOLUTION;INTRAMUSCULAR, INTRAVENOUS Prescription
10MG/ML (10MG/ML) SOLUTION;INTRAMUSCULAR, INTRAVENOUS Prescription

58. Drug name - NATESTO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11090312 ACERUS Methods of treating hypogonadism with transnasal testerosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event Mar, 2034

(11 years from now)

Drugs and Companies using TESTOSTERONE ingredient

Treatment: Nasal administration of a testosterone gel to a patient to treat the patient for a condition associated with a deficiency or absence of endogenous testosterone

Dosage: GEL, METERED;NASAL

More Information on Dosage
Strength Dosage Availability
5.5MG/0.122GM ACTUATION GEL, METERED;NASAL Prescription

59. Drug name - OMIDRIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9066856

(Pediatric)

RAYNER SURGICAL Stable preservative-free mydriatic and anti-inflammatory solutions for injection Apr, 2034

(11 years from now)

US9486406

(Pediatric)

RAYNER SURGICAL Stable preservative-free mydriatic and anti-inflammatory solutions for injection Apr, 2034

(11 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 0.3% BASE;EQ 1% BASE SOLUTION;IRRIGATION Prescription

60. Drug name - ONZETRA XSAIL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10076614 CURRAX Nasal delivery devices Oct, 2034

(12 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 11MG BASE POWDER;NASAL Prescription

61. Drug name - ORIAHNN (COPACKAGED)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10881659 ABBVIE INC Methods of treating heavy menstrual bleeding Mar, 2034

(11 years from now)

US11045470 ABBVIE INC Methods of treating heavy menstrual bleeding Mar, 2034

(11 years from now)

Drugs and Companies using ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX SODIUM ingredient

Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids)

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 300MG BASE,1MG,0.5MG; EQ 300MG BASE CAPSULE;ORAL Prescription

62. Drug name - OTEZLA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10092541 AMGEN INC Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast May, 2034

(11 years from now)

US9872854 AMGEN INC Methods for the treatment of psoriatic arthritis using apremilast May, 2034

(11 years from now)

Drugs and Companies using APREMILAST ingredient

Treatment: Treatment of psoriasis using a dosage titration schedule; treatment of adult patients with oral ulcers associated with behcet's disease using a dosage titration schedule; Treatment of psoriatic arthritis using a dosage titration schedule; treatment of psoriatic arthritis with apremilast using a dosage titration schedule and a second active agent

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET;ORAL Prescription
20MG TABLET;ORAL Prescription
30MG TABLET;ORAL Prescription

63. Drug name - OXBRYTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9248199 GLOBAL BLOOD THERAPS 1:1 adducts of sickle hemoglobin Jan, 2034

(11 years from now)

Drugs and Companies using VOXELOTOR ingredient

Treatment: Treatment of sickle cell disease by administering voxelotor, as recited in claim 1; treatment of sickle cell disease by administering voxelotor, as recited in claim 2

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
500MG TABLET;ORAL Prescription

64. Drug name - OXLUMO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9828606 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(12 years from now)

US10465195 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(12 years from now)

US10487330 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(12 years from now)

US11060093 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(12 years from now)

EP3087184B1 ALNYLAM PHARMS INC Methods And Compositions For The Specific Inhibition Of Glycolate Oxidase (Hao1) By Double-Stranded Rna
Dec, 2034

(12 years from now)

EP3087184A4 ALNYLAM PHARMS INC Methods And Compositions For The Specific Inhibition Of Glycolate Oxidase (Hao1) By Double-Stranded Rna
Dec, 2034

(12 years from now)

EP3087184A1 ALNYLAM PHARMS INC Methods And Compositions For The Specific Inhibition Of Glycolate Oxidase (Hao1) By Double-Stranded Rna
Dec, 2034

(12 years from now)

EP3581654A1 ALNYLAM PHARMS INC Methods And Compositions For The Specific Inhibition Of Glycolate Oxidase (Hao1) By Double-Stranded Rna
Dec, 2034

(12 years from now)

EP3581654B1 ALNYLAM PHARMS INC Methods And Compositions For The Specific Inhibition Of Glycolate Oxidase (Hao1) By Double-Stranded Rna
Dec, 2034

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10435692 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA Dec, 2034

(12 years from now)

Drugs and Companies using LUMASIRAN SODIUM ingredient

Treatment: Treatment of primary hyperoxaluria type 1 (ph1)

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 94.5MG/0.5ML BASE (EQ 94.5MG/0.5ML BASE) SOLUTION;SUBCUTANEOUS Prescription

65. Drug name - PARSABIV

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10344765 KAI PHARMS INC Stable liquid formulation of AMG 416 (etelcalcetide) Jun, 2034

(11 years from now)

US9820938 KAI PHARMS INC Stable liquid formulation of AMG 416 (etelcalcetide) Jun, 2034

(11 years from now)

US11162500 KAI PHARMS INC Stable liquid formulation of AMG 416 (etelcalcetide) Jun, 2034

(11 years from now)

Drugs and Companies using ETELCALCETIDE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
2.5MG/0.5ML (2.5MG/0.5ML) SOLUTION;INTRAVENOUS Prescription
5MG/ML (5MG/ML) SOLUTION;INTRAVENOUS Prescription
10MG/2ML (5MG/ML) SOLUTION;INTRAVENOUS Prescription

66. Drug name - PROCYSBI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9173851 HORIZON Delayed release cysteamine bead formulation, and methods of making and using same Jun, 2034

(11 years from now)

US9233077 HORIZON Delayed release cysteamine bead formulation, and methods of making and using same Jun, 2034

(11 years from now)

US9173851

(Pediatric)

HORIZON Delayed release cysteamine bead formulation, and methods of making and using same Dec, 2034

(12 years from now)

US9233077

(Pediatric)

HORIZON Delayed release cysteamine bead formulation, and methods of making and using same Dec, 2034

(12 years from now)

Drugs and Companies using CYSTEAMINE BITARTRATE ingredient

Treatment: NA

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 25MG BASE CAPSULE, DELAYED RELEASE;ORAL Prescription
EQ 75MG BASE CAPSULE, DELAYED RELEASE;ORAL Prescription

67. Drug name - PROCYSBI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9173851 HORIZON PHARMA USA Delayed release cysteamine bead formulation, and methods of making and using same Jun, 2034

(11 years from now)

US9233077 HORIZON PHARMA USA Delayed release cysteamine bead formulation, and methods of making and using same Jun, 2034

(11 years from now)

US9173851

(Pediatric)

HORIZON PHARMA USA Delayed release cysteamine bead formulation, and methods of making and using same Dec, 2034

(12 years from now)

US9233077

(Pediatric)

HORIZON PHARMA USA Delayed release cysteamine bead formulation, and methods of making and using same Dec, 2034

(12 years from now)

Drugs and Companies using CYSTEAMINE BITARTRATE ingredient

Treatment: NA

Dosage: GRANULE, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 75MG BASE/PACKET GRANULE, DELAYED RELEASE;ORAL Prescription
EQ 300MG BASE/PACKET GRANULE, DELAYED RELEASE;ORAL Prescription

68. Drug name - RAYALDEE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10357502 EIRGEN Stabilized modified release vitamin D formulation and method of administering same Mar, 2034

(11 years from now)

US11253528 EIRGEN Stabilized modified release Vitamin D formulation and method of administering same Mar, 2034

(11 years from now)

US9861644 EIRGEN Stabilized modified release vitamin D formulation and method of administering same Mar, 2034

(11 years from now)

US10300078 EIRGEN Stabilized modified release vitamin D formulation and method of administering same Mar, 2034

(11 years from now)

Drugs and Companies using CALCIFEDIOL ingredient

Treatment: NA

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
0.03MG CAPSULE, EXTENDED RELEASE;ORAL Prescription

69. Drug name - RESTASIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9676525 ALLERGAN Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids Feb, 2034

(11 years from now)

US9669974 ALLERGAN Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids May, 2034

(11 years from now)

Drugs and Companies using CYCLOSPORINE ingredient

Treatment: NA

Dosage: EMULSION;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.05% EMULSION;OPHTHALMIC Prescription

70. Drug name - RHOPRESSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9931336 AERIE PHARMS INC Combination therapy
Mar, 2034

(11 years from now)

US10588901 AERIE PHARMS INC Combination therapy
Mar, 2034

(11 years from now)

US9415043 AERIE PHARMS INC Combination therapy
Mar, 2034

(11 years from now)

CN109528721A AERIE PHARMS INC Combination Therapy
Mar, 2034

(11 years from now)

CN109528721B AERIE PHARMS INC Combination Therapy
Mar, 2034

(11 years from now)

EP2976080B1 AERIE PHARMS INC Conjugates Of Isoquinoline Compounds And Prostaglandins
Mar, 2034

(11 years from now)

EP2976080A1 AERIE PHARMS INC Conjugates Of Isoquinoline Compounds And Prostaglandins
Mar, 2034

(11 years from now)

EP3461484B1 AERIE PHARMS INC Dimesylate Salts Of 4-(3-Amino-1-(Isoquinolin-6-Ylamino)-1-Oxopropan-2-Yl)Benzyl, Their Combinations With Prostaglandins And The Use Thereof In The Treatment Of Ocular Disorders
Mar, 2034

(11 years from now)

EP3461484B9 AERIE PHARMS INC Dimesylate Salts Of 4-(3-Amino-1-(Isoquinolin-6-Ylamino)-1-Oxopropan-2-Yl)Benzyl, Their Combinations With Prostaglandins And The Use Thereof In The Treatment Of Ocular Disorders
Mar, 2034

(11 years from now)

EP3461484A1 AERIE PHARMS INC Dimesylate Salts Of 4-(3-Amino-1-(Isoquinolin-6-Ylamino)-1-Oxopropan-2-Yl)Benzyl, Their Combinations With Prostaglandins And The Use Thereof In The Treatment Of Ocular Disorders
Mar, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11185538 AERIE PHARMS INC Compositions for treating glaucoma or reducing intraocular pressure Mar, 2034

(11 years from now)

Drugs and Companies using NETARSUDIL MESYLATE ingredient

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
EQ 0.02% BASE SOLUTION/DROPS;OPHTHALMIC Prescription

71. Drug name - ROCKLATAN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9993470 AERIE PHARMS INC Combination therapy
Mar, 2034

(11 years from now)

US9931336 AERIE PHARMS INC Combination therapy
Mar, 2034

(11 years from now)

US10588901 AERIE PHARMS INC Combination therapy
Mar, 2034

(11 years from now)

US9415043 AERIE PHARMS INC Combination therapy
Mar, 2034

(11 years from now)

CN109528721A AERIE PHARMS INC Combination Therapy
Mar, 2034

(11 years from now)

CN109528721B AERIE PHARMS INC Combination Therapy
Mar, 2034

(11 years from now)

EP2976080B1 AERIE PHARMS INC Conjugates Of Isoquinoline Compounds And Prostaglandins
Mar, 2034

(11 years from now)

EP2976080A1 AERIE PHARMS INC Conjugates Of Isoquinoline Compounds And Prostaglandins
Mar, 2034

(11 years from now)

EP3461484B1 AERIE PHARMS INC Dimesylate Salts Of 4-(3-Amino-1-(Isoquinolin-6-Ylamino)-1-Oxopropan-2-Yl)Benzyl, Their Combinations With Prostaglandins And The Use Thereof In The Treatment Of Ocular Disorders
Mar, 2034

(11 years from now)

EP3461484B9 AERIE PHARMS INC Dimesylate Salts Of 4-(3-Amino-1-(Isoquinolin-6-Ylamino)-1-Oxopropan-2-Yl)Benzyl, Their Combinations With Prostaglandins And The Use Thereof In The Treatment Of Ocular Disorders
Mar, 2034

(11 years from now)

EP3461484A1 AERIE PHARMS INC Dimesylate Salts Of 4-(3-Amino-1-(Isoquinolin-6-Ylamino)-1-Oxopropan-2-Yl)Benzyl, Their Combinations With Prostaglandins And The Use Thereof In The Treatment Of Ocular Disorders
Mar, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11197853 AERIE PHARMS INC Combination therapy Mar, 2034

(11 years from now)

US11185538 AERIE PHARMS INC Compositions for treating glaucoma or reducing intraocular pressure Mar, 2034

(11 years from now)

More Information on Dosage
Strength Dosage Availability
0.005%;EQ 0.02% BASE SOLUTION/DROPS;OPHTHALMIC Prescription

72. Drug name - RYALTRIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10758550 GLENMARK SPECIALTY Treatment of allergic rhinitis using a combination of mometasone and olopatadine Sep, 2034

(11 years from now)

US10765686 GLENMARK SPECIALTY Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine Sep, 2034

(11 years from now)

US10646500 GLENMARK SPECIALTY Treatment of allergic rhinitis using a combination of mometasone and olopatadine Sep, 2034

(11 years from now)

US10548907 GLENMARK SPECIALTY Treatment of allergic rhinitis using a combination of mometasone and olopatadine Sep, 2034

(11 years from now)

US10016443 GLENMARK SPECIALTY Treatment of allergic rhinitis using a combination of mometasone and olopatadine Sep, 2034

(11 years from now)

US10517880 GLENMARK SPECIALTY Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine Sep, 2034

(11 years from now)

US9750754 GLENMARK SPECIALTY Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine Sep, 2034

(11 years from now)

US9078923 GLENMARK SPECIALTY Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine Sep, 2034

(11 years from now)

US9937189 GLENMARK SPECIALTY Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine Sep, 2034

(11 years from now)

US10376526 GLENMARK SPECIALTY Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine Sep, 2034

(11 years from now)

US9370483 GLENMARK SPECIALTY Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine Sep, 2034

(11 years from now)

US10561672 GLENMARK SPECIALTY Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine Sep, 2034

(11 years from now)

Drugs and Companies using MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE ingredient

Treatment: Treatment of seasonal allergic rhinitis by nasaly administering a combination of olopatadine hydrochloride and mometasone furoate to a pediatric patient; Method of delivering a combination of olopatadine hydrochloride and mometasone furoate to a nasal airway; Treatment of seasonal allergic rhinitis by nasaly administering a combination of olopatadine hydrochloride and mometasone furoate

Dosage: SPRAY, METERED;NASAL

More Information on Dosage
Strength Dosage Availability
0.025MG/SPRAY;0.665MG/SPRAY SPRAY, METERED;NASAL Prescription

73. Drug name - RYBELSUS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10278923 NOVO Oral dosing of GLP-1 compounds May, 2034

(11 years from now)

Drugs and Companies using SEMAGLUTIDE ingredient

Treatment: Method of treating type 2 diabetes mellitus

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
3MG TABLET;ORAL Prescription
7MG TABLET;ORAL Prescription
14MG TABLET;ORAL Prescription

74. Drug name - SINUVA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10406332 INTERSECT ENT INC Systems, devices, and method for treating a sinus condition Mar, 2034

(11 years from now)

US10232152 INTERSECT ENT INC Systems, devices, and method for treating a sinus condition Nov, 2034

(12 years from now)

Drugs and Companies using MOMETASONE FUROATE ingredient

Treatment: Treatment of nasal polyps in patients >=18 years of age who have had ethmoid sinus surgery using a corticosteroid-eluting (mometasone furoate) implant

Dosage: IMPLANT;IMPLANTATION

More Information on Dosage
Strength Dosage Availability
1.35MG IMPLANT;IMPLANTATION Prescription

75. Drug name - SOOLANTRA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9089587 GALDERMA LABS LP Treatment of papulopustular rosacea with ivermectin Mar, 2034

(11 years from now)

US10206939 GALDERMA LABS LP Treatment of papulopustular rosacea with ivermectin Mar, 2034

(11 years from now)

US9782425 GALDERMA LABS LP Treatment of papulopustular rosacea with ivermectin Mar, 2034

(11 years from now)

US9233117 GALDERMA LABS LP Treatment of inflammatory lesions of rosacea with ivermectin Mar, 2034

(11 years from now)

US9233118 GALDERMA LABS LP Treatment of papulopustular rosacea with ivermectin Mar, 2034

(11 years from now)

Drugs and Companies using IVERMECTIN ingredient

Treatment: Treatment of inflammatory lesions of rosacea.

Dosage: CREAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
1% CREAM;TOPICAL Prescription

76. Drug name - SOTYLIZE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10206895 ARBOR PHARMS LLC Sotalol compositions and uses of the same Apr, 2034

(11 years from now)

US11013703 ARBOR PHARMS LLC Sotalol compositions and uses of the same Apr, 2034

(11 years from now)

Drugs and Companies using SOTALOL HYDROCHLORIDE ingredient

Treatment: Sotylize is indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (afib/afl)] in patients with symptomatic afib/afl who are currently in sinus rhythm; indicated for the treatment of ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgement of the physician are life-threatening

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
5MG/ML (5MG/ML) SOLUTION;ORAL Prescription

77. Drug name - SPINRAZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9926559 BIOGEN IDEC Compositions and methods for modulation of SMN2 splicing in a subject Jan, 2034

(11 years from now)

Drugs and Companies using NUSINERSEN SODIUM ingredient

Treatment: Treatment of spinal muscular atrophy

Dosage: SOLUTION;INTRATHECAL

More Information on Dosage
Strength Dosage Availability
EQ 12MG BASE/5ML (EQ 2.4MG BASE/ML) SOLUTION;INTRATHECAL Prescription

78. Drug name - SPRITAM

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9339489 APRECIA PHARMS Rapid disperse dosage form containing levetiracetam Mar, 2034

(11 years from now)

US9669009 APRECIA PHARMS Rapid disperse dosage form containing levetiracetam Mar, 2034

(11 years from now)

US11160786 APRECIA PHARMS Rapid disperse dosage form Mar, 2034

(11 years from now)

Drugs and Companies using LEVETIRACETAM ingredient

Treatment: Method of administering levetiracetam; Method of administering levetiracetam under fasted conditions; method of administering levetiracetam; method of administering levetiracetam under fed conditions

Dosage: TABLET, FOR SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
1GM TABLET, FOR SUSPENSION;ORAL Prescription
250MG TABLET, FOR SUSPENSION;ORAL Prescription
500MG TABLET, FOR SUSPENSION;ORAL Prescription
750MG TABLET, FOR SUSPENSION;ORAL Prescription

79. Drug name - SYNJARDY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof Apr, 2034

(11 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof Apr, 2034

(11 years from now)

Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of treating type 2 diabetes mellitus in a patent with renal impairment (egfr<60 ml/min/1.73 m2) by initiation of empagliflozin and metformin hcl if egfr>=45 ml/min/1.73 m2 and discontinuation if egfr<30 ml/min/1.73 m2

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
5MG;1GM TABLET;ORAL Prescription
5MG;500MG TABLET;ORAL Prescription
12.5MG;1GM TABLET;ORAL Prescription
12.5MG;500MG TABLET;ORAL Prescription

80. Drug name - SYNJARDY XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof Apr, 2034

(11 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof Apr, 2034

(11 years from now)

US9949998 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof Jun, 2034

(11 years from now)

Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of treating type 2 diabetes mellitus in a patent with renal impairment (egfr<60 ml/min/1.73 m2) by initiation of empagliflozin and metformin hcl if egfr>=45 ml/min/1.73 m2 and discontinuation if egfr<30 ml/min/1.73 m2

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
5MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
10MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
12.5MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
25MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription

81. Drug name - TALICIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9050263 REDHILL Pharmaceutical compositions for the treatment of Helicobacter pylori Feb, 2034

(11 years from now)

US9603806 REDHILL Pharmaceutical compositions for the treatment of Helicobacter pylori Feb, 2034

(11 years from now)

US9498445 REDHILL Pharmaceutical compositions for the treatment of Helicobacter pylori Feb, 2034

(11 years from now)

US11135172 REDHILL Rifabutin-based compositions and methods for treating Helicobacter pylori infection Feb, 2034

(11 years from now)

US10238606 REDHILL Pharmaceutical compositions for the treatment of Helicobacter pylori Feb, 2034

(11 years from now)

Drugs and Companies using AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN ingredient

Treatment: Treatment of h. pylori infection in adults

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
250MG;EQ 10MG BASE;12.5MG CAPSULE, DELAYED RELEASE;ORAL Prescription

82. Drug name - TAZVERIK

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9688665 EPIZYME INC Methods of treating cancer Aug, 2034

(11 years from now)

Drugs and Companies using TAZEMETOSTAT HYDROBROMIDE ingredient

Treatment: Method of treating epithelioid sarcoma

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 200MG BASE TABLET;ORAL Prescription

83. Drug name - TEMBEXA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8962829 CHIMERIX Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof
Oct, 2034

(12 years from now)

IN201627019468A CHIMERIX Morphic Forms Of Hexadecyloxypropyl Phosphonate Esters
Oct, 2034

(12 years from now)

IN328711B CHIMERIX A Method Of Preperation Of Morphic Forms Of Hexadecyloxyprop Yl-Phosphonate Esters
Oct, 2034

(12 years from now)

EP2999476A1 CHIMERIX Morphic Forms Of Hexadecyloxypropyl-Phosphonate Esters
Oct, 2034

(12 years from now)

EP2999476A4 CHIMERIX Morphic Forms Of Hexadecyloxypropyl-Phosphonate Esters
Oct, 2034

(12 years from now)

EP2999476B1 CHIMERIX Morphic Forms Of Hexadecyloxypropyl-Phosphonate Esters
Oct, 2034

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10112909 CHIMERIX Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof Oct, 2034

(12 years from now)

US10487061 CHIMERIX Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof Oct, 2034

(12 years from now)

US9371344 CHIMERIX Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof Oct, 2034

(12 years from now)

Drugs and Companies using BRINCIDOFOVIR ingredient

Treatment: Method of treating human smallpox disease

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
100MG TABLET;ORAL Prescription

84. Drug name - TRIJARDY XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof Apr, 2034

(11 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof Apr, 2034

(11 years from now)

US9949998 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof Jun, 2034

(11 years from now)

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin in combination with linagliptin and metformin; Method of treating type 2 diabetes mellitus in a patient with renal impairment (egfr<60 ml/min/1.73 m2) by initiation of empagliflozin, linagliptin and metformin hcl if egfr>=45 ml/min/1.73 m2 and discontinuation if egfr <30 ml/min/1.73 m2

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
5MG;2.5MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
10MG;5MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
12.5MG;2.5MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
25MG;5MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription

85. Drug name - TRULANCE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10011637 SALIX Ultra-pure agonists of guanylate cyclase C, method of making and using same
Jun, 2034

(11 years from now)

CN105764916B SALIX A Hyperpure Agonist Of Guanylate Cyclase C, Preparation And Use Method Of The Agonist
Jun, 2034

(11 years from now)

CN105764916A SALIX A Super-Pure Agonist Of Guanylate Cyclase C, Preparation And Using Method Of The Agonist
Jun, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11142549 SALIX Ultra-pure agonists of guanylate cyclase C, method of making and using same Jun, 2034

(11 years from now)

More Information on Dosage
Strength Dosage Availability
3MG TABLET;ORAL Prescription

86. Drug name - TRUSELTIQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11160804 HELSINN HLTHCARE Pharmaceutical dosage forms Dec, 2034

(12 years from now)

US10278969 HELSINN HLTHCARE Pharmaceutical dosage forms Dec, 2034

(12 years from now)

More Information on Dosage
Strength Dosage Availability
25MG CAPSULE;ORAL Prescription
100MG CAPSULE;ORAL Prescription

87. Drug name - VELPHORO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10624855 VIFOR FRESENIUS Pharmaceutical composition, comprising phosphate binder particles Nov, 2034

(12 years from now)

US11234938 VIFOR FRESENIUS Pharmaceutical composition, comprising phosphate binder particles Nov, 2034

(12 years from now)

Drugs and Companies using FERRIC OXYHYDROXIDE ingredient

Treatment: NA

Dosage: TABLET, CHEWABLE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 500MG IRON TABLET, CHEWABLE;ORAL Prescription

88. Drug name - VOGELXO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8785426 UPSHER SMITH LABS Testosterone gel compositions and related methods Feb, 2034

(11 years from now)

US9662340 UPSHER SMITH LABS Testosterone gel compositions and related methods Feb, 2034

(11 years from now)

US9295675 UPSHER SMITH LABS Testosterone gel compositions and related methods Feb, 2034

(11 years from now)

Drugs and Companies using TESTOSTERONE ingredient

Treatment: Method for transdermal delivery of testosterone

Dosage: GEL, METERED;TRANSDERMAL; GEL;TRANSDERMAL

More Information on Dosage
Strength Dosage Availability
12.5MG/1.25GM ACTUATION GEL, METERED;TRANSDERMAL Prescription
50MG/5GM PACKET GEL;TRANSDERMAL Prescription

89. Drug name - VOSEVI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9296782 GILEAD SCIENCES INC Inhibitors of hepatitis C virus
Jul, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11116783 GILEAD SCIENCES INC Combination formulation of two antiviral compounds Jan, 2034

(11 years from now)

US11116783

(Pediatric)

GILEAD SCIENCES INC Combination formulation of two antiviral compounds Jul, 2034

(11 years from now)

Drugs and Companies using SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR ingredient

Treatment: Treatment of adult patients with chronic hcv infection who have genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an hcv regimen containing an ns5a inhibitor; treatment of adult patients with chronic hcv infection who have genotype 1a or 3 infection and have previously been treated with an hcv regimen containing sofosbuvir without an ns5a inhibitor

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
400MG;100MG;100MG TABLET;ORAL Prescription

90. Drug name - VYXEOS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10028912 CELATOR PHARMS Method of lyophilizing liposomes Sep, 2034

(12 years from now)

Drugs and Companies using CYTARABINE; DAUNORUBICIN ingredient

Treatment: Method of administering a reconstituted liposomal composition containing cytarabine and daunorubicin to treat newly-diagnosed therapy-related aml (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in patients 1 year and older; method of reconstituting a lyophilized liposomal composition for administering cytarabine and daunorubicin to treat newly-diagnosed therapy-related aml (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in patients 1 year and older

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
100MG;44MG POWDER;INTRAVENOUS Prescription

91. Drug name - WELIREG

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9969689 MERCK SHARP DOHME Aryl ethers and uses thereof
Sep, 2034

(11 years from now)

US9908845 MERCK SHARP DOHME Aryl ethers and uses thereof
Sep, 2034

(11 years from now)

CN110372550B MERCK SHARP DOHME Aryl Ether And Use Thereof
Sep, 2034

(11 years from now)

CN110372550A MERCK SHARP DOHME Aryl Ether And Its Use
Sep, 2034

(11 years from now)

CN105530923B MERCK SHARP DOHME Aryl Ether And Its Use
Sep, 2034

(11 years from now)

CN105530923A MERCK SHARP DOHME Aryl Ether And Application
Sep, 2034

(11 years from now)

EP3043784A4 MERCK SHARP DOHME Aryl Ethers And Uses Thereof
Sep, 2034

(11 years from now)

EP3043784A1 MERCK SHARP DOHME Aryl Ethers And Uses Thereof
Sep, 2034

(11 years from now)

EP3417851B1 MERCK SHARP DOHME Aryl Ethers And Uses Thereof
Sep, 2034

(11 years from now)

EP3417852B1 MERCK SHARP DOHME Aryl Ethers And Uses Thereof
Sep, 2034

(11 years from now)

EP3417852A1 MERCK SHARP DOHME Aryl Ethers And Uses Thereof
Sep, 2034

(11 years from now)

EP3417851A1 MERCK SHARP DOHME Aryl Ethers And Uses Thereof
Sep, 2034

(11 years from now)

EP3043784B1 MERCK SHARP DOHME Aryl Ethers And Uses Thereof
Sep, 2034

(11 years from now)

EP3043784B9 MERCK SHARP DOHME Aryl Ethers And Uses Thereof
Sep, 2034

(11 years from now)

Drugs and Companies using BELZUTIFAN ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
40MG TABLET;ORAL Prescription

92. Drug name - XARELTO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9539218 JANSSEN PHARMS Prevention and treatment of thromboembolic disorders Feb, 2034

(11 years from now)

US9539218

(Pediatric)

JANSSEN PHARMS Prevention and treatment of thromboembolic disorders Aug, 2034

(11 years from now)

Drugs and Companies using RIVAROXABAN ingredient

Treatment: Treatment of pulmonary embolism with once daily, rapid-release tablet administered for at least five consecutive days; treatment of deep vein thrombosis with once daily, rapid-release tablet administered for at least five consecutive days; prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism in patients undergoing knee or hip replacement surgery, with once daily, rapid-release tablet administered for at least five consecutive days; reduce the risk of stroke in patients with nonvalvular atrial fibrillation with once daily, rapid-release tablet administered for at least five consecutive days; prophylaxis of venous thromboembolism in acutely ill medical patients at risk for thromboembolic complications not at high risk of bleeding with once daily, rapid-release tablet administered for at least 5 consecutive days; treatment of dvt and/or pe and reduction in the risk of recurrent dvt and/or pe in pediatric patients (>=50 kg) once daily with rapid-release tablet administered for at least 5 consecutive days after at least 5 days parenteral anticoagulant treatment; after completion of initial treatment lasting at least 6 months, to reduce the risk of recurrence of deep vein thrombosis and/or pulmonary embolism in certain patients with once daily, rapid-release tablet administered for at least 5 consecutive days; prophylaxis of pe, dvt and/or stroke in pediatric patients (>=50 kg) aged 2 years and older with congenital heart disease after fontan procedure with once daily, rapid-release tablet administered for at least 5 consecutive days; treatment of dvt and/or pe and reduction in risk of recurrent dvt and/or pe in pediatric patients (30-49.9 kg) once daily with rapid-release tablet administered for at least 5 consecutive days after at least 5 days parenteral anticoagulant treatment

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription
15MG TABLET;ORAL Prescription
20MG TABLET;ORAL Prescription

93. Drug name - XEGLYZE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10292389 DR REDDYS LABS SA Pediculicidal composition Dec, 2034

(12 years from now)

Drugs and Companies using ABAMETAPIR ingredient

Treatment: Topical treatment of head lice infestation in patients 6 months of age and older

Dosage: LOTION;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.74% LOTION;TOPICAL Discontinued

94. Drug name - XELJANZ XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9937181 PFIZER Tofacitinib oral sustained release dosage forms Mar, 2034

(11 years from now)

US10639309 PFIZER Tofacitinib oral sustained release dosage forms Mar, 2034

(11 years from now)

Drugs and Companies using TOFACITINIB CITRATE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 11MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 22MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription

95. Drug name - XHANCE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10076614 OPTINOSE US INC Nasal delivery devices Oct, 2034

(12 years from now)

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Treatment: NA

Dosage: SPRAY, METERED;NASAL

More Information on Dosage
Strength Dosage Availability
0.093MG SPRAY, METERED;NASAL Prescription

96. Drug name - XIPERE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9937075 BAUSCH AND LOMB INC Apparatus and methods for ocular injection May, 2034

(11 years from now)

Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient

Treatment: NA

Dosage: SUSPENSION;INJECTION

More Information on Dosage
Strength Dosage Availability
40MG/ML SUSPENSION;INJECTION Prescription

97. Drug name - XYOSTED (AUTOINJECTOR)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10881798 ANTARES PHARMA INC Needle assisted injection device having reduced trigger force Feb, 2034

(11 years from now)

US11160751 ANTARES PHARMA INC Hematocrit modulation through needle assisted jet injection of testosterone Oct, 2034

(12 years from now)

Drugs and Companies using TESTOSTERONE ENANTHATE ingredient

Treatment: Method of administering testosterone enanthate subcutaneously

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
50MG/0.5ML (50MG/0.5ML) SOLUTION;SUBCUTANEOUS Prescription
75MG/0.5ML (75MG/0.5ML) SOLUTION;SUBCUTANEOUS Prescription
100MG/0.5ML (100MG/0.5ML) SOLUTION;SUBCUTANEOUS Prescription

98. Drug name - YONSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9889144 SUN PHARM Abiraterone acetate formulation and methods of use Mar, 2034

(11 years from now)

US10292990 SUN PHARM Abiraterone steroid formulation May, 2034

(11 years from now)

Drugs and Companies using ABIRATERONE ACETATE ingredient

Treatment: Use in combination with methylprednisolone for the treatment of patients with prostate cancer

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
125MG TABLET;ORAL Prescription

99. Drug name - ZERBAXA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8906898 CUBIST PHARMS LLC Solid forms of ceftolozane
May, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10420841 CUBIST PHARMS LLC Ceftolozane antibiotic compositions Mar, 2034

(11 years from now)

US8968753 CUBIST PHARMS LLC Ceftolozane-tazobactam pharmaceutical compositions Mar, 2034

(11 years from now)

US9872906 CUBIST PHARMS LLC Ceftolozane antibiotic compositions Mar, 2034

(11 years from now)

US9320740 CUBIST PHARMS LLC Ceftolozane-tazobactam pharmaceutical compositions Mar, 2034

(11 years from now)

US10376496 CUBIST PHARMS LLC Treating infections with ceftolozane/tazobactam in subjects having impaired renal function Sep, 2034

(11 years from now)

US10933053 CUBIST PHARMS LLC Treating infections with ceftolozane/tazobactam in subjects having impaired renal function Sep, 2034

(11 years from now)

Drugs and Companies using CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM ingredient

Treatment: Treatment of complicated urinary tract infection; treatment of complicated intra-abdominal infection; Treatment of complicated urinary tract infection, including pyelonephritis; treatment of complicated intra-abdominal infection; Treatment of complicated urinary tract infection in patients with end-stage renal disease on hemodialysis; treatment of complicated intra-abdominal infection in patients with end-stage renal disease on hemodialysis; Treatment of ventilator-associated bacterial pneumonia in patients with end-stage renal disease on hemodialysis; treatment of hospital-acquired bacterial pneumonia in patients with end-stage renal disease on hemodialysis

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL POWDER;INTRAVENOUS Prescription

100. Drug name - ZOHYDRO ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9713611 RECRO GAINESVILLE Abuse resistant pharmaceutical compositions Sep, 2034

(11 years from now)

US9132096 RECRO GAINESVILLE Abuse resistant pharmaceutical compositions Sep, 2034

(11 years from now)

US9452163 RECRO GAINESVILLE Abuse resistant pharmaceutical compositions Sep, 2034

(11 years from now)

US10092559 RECRO GAINESVILLE Abuse resistant pharmaceutical compositions Sep, 2034

(11 years from now)

US9486451 RECRO GAINESVILLE Abuse resistant pharmaceutical compositions Sep, 2034

(11 years from now)

Drugs and Companies using HYDROCODONE BITARTRATE ingredient

Treatment: Treatment of pain

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
10MG CAPSULE, EXTENDED RELEASE;ORAL Discontinued
15MG CAPSULE, EXTENDED RELEASE;ORAL Discontinued
20MG CAPSULE, EXTENDED RELEASE;ORAL Discontinued
30MG CAPSULE, EXTENDED RELEASE;ORAL Discontinued
40MG CAPSULE, EXTENDED RELEASE;ORAL Discontinued
50MG CAPSULE, EXTENDED RELEASE;ORAL Discontinued

101. Drug name - ZURAGARD

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10688291 ZUREX PHARMA Medical skin applicator apparatus Dec, 2034

(12 years from now)

Drugs and Companies using ISOPROPYL ALCOHOL ingredient

Treatment: Use as an antiseptic for the preparation of a patient's skin prior to surgery

Dosage: SOLUTION;TOPICAL

More Information on Dosage
Strength Dosage Availability
70% SOLUTION;TOPICAL Discontinued

102. Drug name - ZYNRELEF KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9592227 HERON THERAPS INC Compositions of a polyorthoester and an aprotic solvent Mar, 2034

(11 years from now)

US9913909 HERON THERAPS INC Compositions of a polyorthoester and an aprotic solvent Mar, 2034

(11 years from now)

US11253504 HERON THERAPS INC Compositions of a polyorthoester and an aprotic solvent Mar, 2034

(11 years from now)

US10398686 HERON THERAPS INC Compositions of a polyorthoester and an aprotic solvent Mar, 2034

(11 years from now)

US9744163 HERON THERAPS INC Compositions of a polyorthoester and an aprotic solvent Mar, 2034

(11 years from now)

Drugs and Companies using BUPIVACAINE; MELOXICAM ingredient

Treatment: Treatment of postsurgical pain providing analgesia to a patient for up to 72 hours, for example, after bunionectomy, open inguinal herniorrhaphy, or total knee arthroplasty via soft tissue or periarticular instillation

Dosage: SOLUTION, EXTENDED RELEASE;PERIARTICULAR

More Information on Dosage
Strength Dosage Availability
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) SOLUTION, EXTENDED RELEASE;PERIARTICULAR Prescription
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) SOLUTION, EXTENDED RELEASE;PERIARTICULAR Prescription
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) SOLUTION, EXTENDED RELEASE;PERIARTICULAR Prescription
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) SOLUTION, EXTENDED RELEASE;PERIARTICULAR Prescription

availability in other generic markets.

Click on the highlighted region to filter.